(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 3.58% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Becton Dickinson & Co's revenue in 2025 is $21,840,000,000.On average, 17 Wall Street analysts forecast BDX's revenue for 2026 to be $6,482,996,967,414, with the lowest BDX revenue forecast at $6,255,232,963,716, and the highest BDX revenue forecast at $6,790,678,165,392. On average, 17 Wall Street analysts forecast BDX's revenue for 2027 to be $6,703,625,507,337, with the lowest BDX revenue forecast at $6,429,052,861,275, and the highest BDX revenue forecast at $7,108,349,012,655.
In 2028, BDX is forecast to generate $6,928,535,325,525 in revenue, with the lowest revenue forecast at $6,596,022,713,610 and the highest revenue forecast at $7,370,934,079,575.